Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by OSE Immunotherapeutics SA

OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors
From OSE Immunotherapeutics SA
Via Business Wire
OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update
From OSE Immunotherapeutics SA
Via Business Wire
OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences
From OSE Immunotherapeutics SA
Via Business Wire
OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting
From OSE Immunotherapeutics SA
Via Business Wire
OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update
From OSE Immunotherapeutics SA
Via Business Wire
OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio
From OSE Immunotherapeutics SA
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.